BR112015027218A2 - tratamento eficaz de nsclc e marcador clínico preditivo da responsividade de um tumor a um tratamento - Google Patents
tratamento eficaz de nsclc e marcador clínico preditivo da responsividade de um tumor a um tratamentoInfo
- Publication number
- BR112015027218A2 BR112015027218A2 BR112015027218A BR112015027218A BR112015027218A2 BR 112015027218 A2 BR112015027218 A2 BR 112015027218A2 BR 112015027218 A BR112015027218 A BR 112015027218A BR 112015027218 A BR112015027218 A BR 112015027218A BR 112015027218 A2 BR112015027218 A2 BR 112015027218A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- nsclc
- effective
- patients
- clinical marker
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 230000004043 responsiveness Effects 0.000 title abstract 3
- 239000003550 marker Substances 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
resumo patente de invenção: "tratamento eficaz de nsclc e marcador clínico preditivo da responsividade de um tumor a um tratamento". a presente invenção refere-se a um tratamento benéfico de tumores em pacientes que sofrem de nsclc, e a um marcador clínico útil como variável preditiva da responsividade dos tumores em pacientes que sofrem de nsclc. a presente invenção adicionalmente diz respeito a um método para selecionar os pacientes prováveis de responder a uma certa terapia, em que o dito método opcionalmente compreende o uso de um marcador clínico específico. a presente invenção adicionalmente diz respeito a um método para tardar a progressão da doença e/ou prolongar a sobrevivência dos pacientes de nsclc, em que o dito método compreende o uso de um marcador clínico específico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13167358 | 2013-05-10 | ||
| PCT/EP2014/059456 WO2014180955A1 (en) | 2013-05-10 | 2014-05-08 | Efficacious treatment of nsclc and predictive clinical marker of the responsiveness of a tumour to a treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015027218A2 true BR112015027218A2 (pt) | 2017-07-25 |
| BR112015027218A8 BR112015027218A8 (pt) | 2018-01-30 |
Family
ID=48236813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015027218A BR112015027218A8 (pt) | 2013-05-10 | 2014-05-08 | tratamento eficaz de nsclc e marcador clínico preditivo da responsividade de um tumor a um tratamento |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20140350022A1 (pt) |
| EP (1) | EP2994125B1 (pt) |
| JP (1) | JP2016518396A (pt) |
| KR (1) | KR20160006226A (pt) |
| CN (1) | CN105188698A (pt) |
| AU (1) | AU2014264533B2 (pt) |
| BR (1) | BR112015027218A8 (pt) |
| CA (1) | CA2911867A1 (pt) |
| CL (1) | CL2015003267A1 (pt) |
| DK (1) | DK2994125T3 (pt) |
| EA (1) | EA034520B1 (pt) |
| ES (1) | ES2693773T3 (pt) |
| HU (1) | HUE040240T2 (pt) |
| MX (1) | MX364523B (pt) |
| PH (1) | PH12015502516A1 (pt) |
| PL (1) | PL2994125T3 (pt) |
| TR (1) | TR201815464T4 (pt) |
| TW (1) | TW201536290A (pt) |
| WO (1) | WO2014180955A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170065529A1 (en) | 2015-09-09 | 2017-03-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical dosage form for immediate release of an indolinone derivative |
| WO2017097697A1 (en) * | 2015-12-08 | 2017-06-15 | Boehringer Ingelheim International Gmbh | Method using a ret fusion gene as a biomarker to select non-small cell lung cancer (nsclc) and thyroid cancer patients for a cancer treatment |
| CN110573161A (zh) * | 2017-03-28 | 2019-12-13 | 勃林格殷格翰国际有限公司 | 用于治疗肌营养不良的方法的尼达尼布 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA75054C2 (uk) | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
| DE10233500A1 (de) * | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
| DE10237423A1 (de) | 2002-08-16 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| EP1870400A1 (en) | 2006-06-08 | 2007-12-26 | Boehringer Ingelheim Pharma GmbH & Co. KG | Salts and crystalline salt forms of an 2-indolinone derivative |
| PE20091445A1 (es) | 2007-12-03 | 2009-10-19 | Boehringer Ingelheim Int | Derivados de indolinona y procedimiento para su fabricacion |
| TR201802086T4 (tr) | 2007-12-03 | 2018-03-21 | Boehringer Ingelheim Int | Bir indolinon türevinin imalatı için proses. |
| UA107560C2 (uk) | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
| JP5993573B2 (ja) * | 2008-06-06 | 2016-09-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組み合わせ |
| PL2299987T3 (pl) | 2008-06-06 | 2018-08-31 | Boehringer Ingelheim International Gmbh | Farmaceutyczna postać dawkowania w formie kapsułki zawierająca formulację zwiesiny pochodnej indolinonu |
| US8802384B2 (en) | 2009-03-12 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method or system using biomarkers for the monitoring of a treatment |
-
2014
- 2014-05-02 US US14/267,978 patent/US20140350022A1/en not_active Abandoned
- 2014-05-08 CN CN201480025036.3A patent/CN105188698A/zh active Pending
- 2014-05-08 EA EA201501095A patent/EA034520B1/ru not_active IP Right Cessation
- 2014-05-08 TR TR2018/15464T patent/TR201815464T4/tr unknown
- 2014-05-08 KR KR1020157035058A patent/KR20160006226A/ko not_active Application Discontinuation
- 2014-05-08 MX MX2015015525A patent/MX364523B/es active IP Right Grant
- 2014-05-08 DK DK14721905.9T patent/DK2994125T3/en active
- 2014-05-08 PL PL14721905T patent/PL2994125T3/pl unknown
- 2014-05-08 BR BR112015027218A patent/BR112015027218A8/pt not_active IP Right Cessation
- 2014-05-08 HU HUE14721905A patent/HUE040240T2/hu unknown
- 2014-05-08 EP EP14721905.9A patent/EP2994125B1/en not_active Revoked
- 2014-05-08 JP JP2016512381A patent/JP2016518396A/ja active Pending
- 2014-05-08 CA CA2911867A patent/CA2911867A1/en not_active Abandoned
- 2014-05-08 ES ES14721905.9T patent/ES2693773T3/es active Active
- 2014-05-08 WO PCT/EP2014/059456 patent/WO2014180955A1/en active Application Filing
- 2014-05-08 AU AU2014264533A patent/AU2014264533B2/en not_active Ceased
- 2014-05-09 TW TW103116628A patent/TW201536290A/zh unknown
-
2015
- 2015-11-03 PH PH12015502516A patent/PH12015502516A1/en unknown
- 2015-11-06 CL CL2015003267A patent/CL2015003267A1/es unknown
-
2016
- 2016-01-29 US US15/010,115 patent/US20160143906A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2994125A1 (en) | 2016-03-16 |
| MX2015015525A (es) | 2016-02-05 |
| WO2014180955A1 (en) | 2014-11-13 |
| EA034520B1 (ru) | 2020-02-17 |
| KR20160006226A (ko) | 2016-01-18 |
| ES2693773T3 (es) | 2018-12-13 |
| PL2994125T3 (pl) | 2019-05-31 |
| HUE040240T2 (hu) | 2019-03-28 |
| EP2994125B1 (en) | 2018-08-01 |
| CN105188698A (zh) | 2015-12-23 |
| US20160143906A1 (en) | 2016-05-26 |
| TW201536290A (zh) | 2015-10-01 |
| BR112015027218A8 (pt) | 2018-01-30 |
| CL2015003267A1 (es) | 2016-07-15 |
| TR201815464T4 (tr) | 2018-11-21 |
| AU2014264533A1 (en) | 2015-10-29 |
| JP2016518396A (ja) | 2016-06-23 |
| AU2014264533B2 (en) | 2019-07-18 |
| US20140350022A1 (en) | 2014-11-27 |
| CA2911867A1 (en) | 2014-11-13 |
| DK2994125T3 (en) | 2018-11-05 |
| MX364523B (es) | 2019-04-30 |
| PH12015502516A1 (en) | 2016-02-29 |
| EA201501095A1 (ru) | 2016-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014023162A8 (pt) | compostos e métodos para modulação quinase e indicações dos mesmos | |
| CY1119960T1 (el) | Μεθοδοι για την αυξηση της αποτελεσματικοτητας της folr1 θεραπειας του καρκινου | |
| BR112015020804A2 (pt) | dispositivo fototerapeutico, método e uso | |
| BR112017016952A2 (pt) | terapia de combinação com fatores de coagulação e anticorpos multiespecíficos | |
| BR112014011465A2 (pt) | modulação de determinadas quinases de tirosina | |
| BR112016012713A2 (pt) | Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento | |
| BR112014014783A2 (pt) | moléculas de inibidor de jnk para tratamento de várias doenças | |
| BR112015012295A8 (pt) | Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer | |
| EA201491584A1 (ru) | Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor | |
| BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
| BR112014031088A2 (pt) | métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal | |
| CO6690781A2 (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| BR112015000776A2 (pt) | Agentes de ligação à rspo3 e usos dos mesmos | |
| BR112016002000A2 (pt) | Diagnóstico e terapia de câncer envolvendo células-tronco tumorais | |
| BR112015011679A2 (pt) | almofada portátil | |
| AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
| BR112016018205A8 (pt) | métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente | |
| BR112015026021A2 (pt) | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| BR112015017775A2 (pt) | enzima cistationina beta-sintase para o tratamento de homocistinúria | |
| BR112015010220A2 (pt) | métodos de utilização de biomarcadores para tratamento de câncer | |
| BR112012032721A2 (pt) | compostos heterocíclicos, sua preparação e sua aplicação terapêutica | |
| BR112014001170A2 (pt) | cateter, especialmente um cateter permanente, para tratamento de problemas funcionais e/ou doenças da bexiga e/ou próstata | |
| BR112017007138A2 (pt) | composto, medicamento, métodos para reduzir proteína 4 de ligação ao retinol e para a profilaxia ou o tratamento de degeneração macular e/ou uma doença, e, uso de um composto. | |
| BR112014029338A2 (pt) | biomarcadores para determinação da resposta eficaz dos tratamentos de pacientes com carcinoma hepatocelular (hcc) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2645 DE 14/09/2021 POR TER SIDO INDEVIDA. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2669 DE 03-03-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |